Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay

Autor: Zsuzsanna Bago-Horvath, Ralf Kronenwett, Katja Specht, Ulrich Lehmann, Peter Schraml, Gudrun Schlake, Bruno Valentin Sinn, Holger Moch, Peter Schirmacher, W. Schlake, Berit Maria Müller, Zsuzsanna Varga, Hans Kreipe, Martin Filipits, Carsten Denkert, Judith Prinzler, Manfred Dietel, Christoph Petry, Marcus Schmidt, Karsten Weber, Roland Penzel, Dontscho Kerjaschki, Frank Tiecke, Kerstin Bohmann, Margaretha Rudas, Heinz Höfler
Přispěvatelé: University of Zurich, Denkert, C
Rok vydání: 2012
Předmět:
Oncology
medicine.medical_specialty
Tissue Fixation
Receptor
ErbB-2

mRNA
Concordance
Breast Neoplasms
610 Medicine & health
Biology
Bioinformatics
Sensitivity and Specificity
Pathology and Forensic Medicine
1307 Cell Biology
Multigene expression
symbols.namesake
Breast cancer
Risk Factors
10049 Institute of Pathology and Molecular Pathology
Internal medicine
Gene expression
Biomarkers
Tumor

1312 Molecular Biology
medicine
Proficiency testing
Cluster Analysis
Humans
Pathology
Molecular

Molecular Biology
Paraffin Embedding
Reverse Transcriptase Polymerase Chain Reaction
Molecular pathology
Gene Expression Profiling
Quality control
Cell Biology
General Medicine
Prognosis
medicine.disease
Pearson product-moment correlation coefficient
2734 Pathology and Forensic Medicine
Receptors
Estrogen

symbols
RNA
Female
Original Article
Kappa
Zdroj: Virchows Archiv
ISSN: 1432-2307
0945-6317
Popis: Gene expression profiles provide important information about the biology of breast tumors and can be used to develop prognostic tests. However, the implementation of quantitative RNA-based testing in routine molecular pathology has not been accomplished, so far. The EndoPredict assay has recently been described as a quantitative RT-PCR-based multigene expression test to identify a subgroup of hormone–receptor-positive tumors that have an excellent prognosis with endocrine therapy only. To transfer this test from bench to bedside, it is essential to evaluate the test–performance in a multicenter setting in different molecular pathology laboratories. In this study, we have evaluated the EndoPredict (EP) assay in seven different molecular pathology laboratories in Germany, Austria, and Switzerland. A set of ten formalin-fixed paraffin-embedded tumors was tested in the different labs, and the variance and accuracy of the EndoPredict assays were determined using predefined reference values. Extraction of a sufficient amount of RNA and generation of a valid EP score was possible for all 70 study samples (100%). The EP scores measured by the individual participants showed an excellent correlation with the reference values, respectively, as reflected by Pearson correlation coefficients ranging from 0.987 to 0.999. The Pearson correlation coefficient of all values compared to the reference value was 0.994. All laboratories determined EP scores for all samples differing not more than 1.0 score units from the pre-defined references. All samples were assigned to the correct EP risk group, resulting in a sensitivity and specificity of 100%, a concordance of 100%, and a kappa of 1.0. Taken together, the EndoPredict test could be successfully implemented in all seven participating laboratories and is feasible for reliable decentralized assessment of gene expression in luminal breast cancer.
Databáze: OpenAIRE